Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
CONCLUSIONS: Our findings highlight differences in patient characteristics (older, more previous pertuzumab therapy) and outcomes (shorter OS) from the T-DM1 pivotal trial and provide real-world estimates that can inform patient, clinician and policy, decisions around the use of HER2-targeted therapies in routine clinical care.PMID:33992964 | DOI:10.1016/j.breast.2021.05.001
Source: Breast - Category: Cancer & Oncology Authors: Benjamin Daniels Belinda E Kiely Monica Tang Nehmat Houssami Sarah J Lord Sallie-Anne Pearson Source Type: research
More News: Australia Health | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Herceptin | Study